AAOS Explores a Post-COVID Return to Normal. It Won’t Be Easy

article image

As a prolonged pandemic takes its toll, a subdued AAOS met to look ahead at the impact of regulatory and reimbursement changes on different aspects of orthopedics, including orthobiologics and the scientific advances that are rapidly changing the regenerative medicine field.

The American Association of Orthopedic Surgeons’ (AAOS) annual meeting in San Diego in late August/early September, was a first in many respects—one of the first major medical meetings to go live, in-person only, and for many attendees it was the first pandemic-era business trip.It was a brave, stubborn, and ultimately informative event that highlighted the organization’s pressing priorities as its members manage through COVID-19 and, even more urgently, reimbursement shifts that are driving structural changes in their practices. (See “Canaccord’s Kyle Rose Previews Innovation, COVID-Era Uncertainty at Upcoming AAOS,” MedTech Strategist, August 26, 2021.)


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: